title: Attenuation of bleomycin-induced Hprt mutant frequency in female and male rats by calorie restriction.
abstract: Calorie restriction modulates spontaneous and chemically induced tumors and increases maximal life span in experimental animals; however, the mechanism by which calorie restriction exerts its ameliorating effects is not fully elucidated, although reduced levels of reactive oxygen species (ROS) by calorie restriction has generated much interest. In the present study, we have determined whether or not calorie restriction would affect the mutagenic response in rats treated with bleomycin (BLM) a radiomimetic drug that is associated with DNA damage by a free radical mechanism. Fourteen weeks after weaning, the rats were divided into two groups; ad libitum (AL)-fed and 40% calorie restriction. Both AL and calorie-restricted animals were injected with 2.5, 5.0 and 10.0 mg BLM/kg, or with phosphate-buffered saline (PBS), and they were killed 4 weeks post drug treatment. Lymphocytes from the spleens were seeded in 96-well microtiter plates to determine mutant frequency in the hypoxantine guanine phosphoribosyl transferase (Hprt) gene. The mutant frequency in the BLM-treated rats was higher in AL males (P=0.001), and AL females (P=0.0174) than in their calorie-restricted counterparts. The difference in mutagenic response relative to AL males and AL females appeared unrelated to a low percent cloning efficiency seen in the males, since the mean absolute number of Hprt mutant clones was higher in the AL males compared to the females. A reduction in animal weight by calorie restriction was significant in both sexes (P<0.001), but the dose effect appeared non-significant. The results indicate that calorie intake of 60% reduced the mutagenic response of BLM, a compound known to induce oxidative DNA damage, and suggest a possible decrease in ROS as a function of calorie restriction.
authors.affiliation: Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA. aaidoo@nctr.fda.gov
authors.forename: A
authors.initials: A
authors.lastname: Aidoo
authors.forename: V G
authors.initials: VG
authors.lastname: Desai
authors.forename: L E
authors.initials: LE
authors.lastname: Lyn-Cook
authors.forename: J J
authors.initials: JJ
authors.lastname: Chen
authors.forename: R J
authors.initials: RJ
authors.lastname: Feuers
authors.forename: D A
authors.initials: DA
authors.lastname: Casciano
mesh_terms: D000818:Animals; D001761:Bleomycin / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects / Q000235:genetics; D002478:Cells, Cultured; D004038:Diet, Reducing; D002149:Energy Intake / Q000187:drug effects*; D005260:Female; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics* / Q000378:metabolism*; D008297:Male; D016296:Mutagenesis / Q000187:drug effects* / Q000235:genetics; D009152:Mutagenicity Tests; D051381:Rats; D011916:Rats, Inbred F344; D017382:Reactive Oxygen Species; D012737:Sex Factors
chemical_list: D017382:Reactive Oxygen Species; D001761:Bleomycin; D007041:Hypoxanthine Phosphoribosyltransferase